Antoñanzas Fernando, Oliva Juan, Pinillos Mariola, Juàrez Carmelo
Department of Economics and Business Administration, Universidad de La Rioja, C/ La Cigüeña 60, 26004, Logroño, Spain.
Eur J Health Econ. 2007 Sep;8(3):297-300. doi: 10.1007/s10198-007-0050-9.
In this article, we provide readers with a summary of the main economic features of the recently approved Spanish law regarding pharmaceutical preparations entitled the Law of Guarantees and Rational Use of Pharmaceuticals and Health Products (Law 29/2006 of July 26th). We review information on pricing, reference pricing, promotion of generic drugs, public reimbursement, patients' contributions, and penalties. Other aspects of minor economic relevance such as the information on prices shown in the packs and the transparency on the results of clinical trials irrespective of whether these are positive or not, are not addressed in this paper. We conclude with some observations on the new horizons opened up by this new legal framework. We have not included any detailed references to the new law; we merely wish to comment on certain aspects of its application.
在本文中，我们向读者概述了最近获批的西班牙关于药品制剂的法律（《药品和健康产品保障与合理使用法》，2006年7月26日第29/2006号法律）的主要经济特征。我们回顾了有关定价、参考定价、仿制药推广、公共报销、患者自付费用以及处罚方面的信息。本文未涉及其他经济相关性较小的方面，例如药品包装上显示的价格信息以及无论临床试验结果是阳性还是阴性时的透明度。我们最后对这一新法律框架所开启的新前景发表了一些看法。我们未对新法律进行任何详细引用；我们只是希望对其应用的某些方面发表评论。
